Creating a New Standard of Care for HF Management
Heart failure (HF) is a major cause of hospitalizations in the United States—someone is hospitalized for HF every 30 seconds.9 An estimated 5.7 million American adults are affected by HF, a figure that is estimated to rise to at least 8 million by the year 2030.10 Every year in the U.S., approximately 1 million patients are hospitalized with a primary discharge diagnosis of HF, and each year HF is a contributing factor in 1 in 9 U.S. deaths.11
Our HF portfolio focuses on a continuum of care for heart failure management. Addressing patients’ needs earlier can mean potentially preventing worsening HF and hospitalization. To help meet this need, our heart failure management portfolio includes the revolutionary CardioMEMS™ HF System for PA monitoring, as well as first-to-market, exclusive quadripolar cardiac resynchronization therapy products with MultiPoint™ pacing technology.
In addition to delivering products for earlier detection and treatment, we also offer a proven, patient-centric LVAD for destination and bridge-to-transplantation therapy.